Search results
Showing 481 to 495 of 537 results for syndrome
This guideline covers assessing and managing heavy menstrual bleeding (menorrhagia). It aims to help healthcare professionals investigate the cause of heavy periods that are affecting a woman’s quality of life and to offer the right treatments, taking into account the woman’s priorities and preferences.
Urinary tract infection in under 16s: diagnosis and management (NG224)
This guideline covers diagnosing and managing first or recurrent upper or lower urinary tract infection (UTI) in babies, children and young people under 16. It aims to achieve more consistent clinical practice, based on accurate diagnosis and effective management. It does not cover babies, children and young people with urinary catheters in situ, neurogenic bladders, significant pre-existing urinary tract disorders (uropathies), underlying renal disease or immunosuppression, or recurrent UTI in sexually active girls and young women under 16. It also does not cover babies, children and young people in intensive care units.
Secondary prevention in acute coronary syndrome: rivaroxaban (ESNM27)
This evidence summary has been replaced by NICE technology appraisal guidance 335
Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts (TA399)
Evidence-based recommendations on azacitidine (Vidaza) for treating acute myeloid leukaemia with more than 30% bone marrow blasts.
This guideline covers the short-term management of violence and aggression in adults (aged 18 and over), young people (aged 13 to 17) and children (aged 12 and under). It is relevant for mental health, health and community settings. The guideline aims to safeguard both staff and people who use services by helping to prevent violent situations and providing guidance to manage them safely when they occur.
Irritable bowel syndrome with constipation in adults: linaclotide (ESNM16)
This evidence summary has been updated and replaced by NICE guideline CG61.
Eluxadoline for treating irritable bowel syndrome with diarrhoea (TA471)
We have withdrawn this guidance. Allergan has stopped marketing eluxadoline (Truberzi) for commercial reasons and its marketing authorisation has been withdrawn.
Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)
This guideline covers the diagnosis and management of type 1 and type 2 diabetes in children and young people aged under 18. The guideline recommends how to support children and young people and their families and carers to maintain tight control of blood glucose to reduce the long-term risks associated with diabetes.
NICE has developed a medtech innovation briefing (MIB) on the Aquilion PRIME CT scanner for imaging coronary artery disease in adults in whom imaging is difficult .
NICE has developed a medtech innovation briefing (MIB) on the Somatom Definition Edge CT scanner for imaging coronary artery disease in adults in whom imaging is difficult .
This guideline covers managing and monitoring diabetic retinopathy in people under the care of hospital eye services. This includes non-proliferative and proliferative diabetic retinopathy, and diabetic macular oedema.
HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography (HTG429)
Evidence-based recommendations on HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography.
NICE has developed a medtech innovation briefing (MIB) on Peptest for diagnosing gastro-oesophageal reflux
Non-Hodgkin's lymphoma: rituximab subcutaneous injection (ESNM46)
Summary of the evidence on rituximab subcutaneous injection for non-Hodgkin's lymphoma in adults to inform local NHS planning and decision-making
Evidence-based recommendations on dabigatran etexilate (Pradaxa) for treating and preventing deep vein thrombosis and pulmonary embolism in adults.